FCPT Announces Acquisition of Six Novant Health Urgent Care Properties for $12.0 Million
Novant Health is an integrated network of more than 900 locations, including 19 hospitals, more than 750 physician clinics and urgent care centers, outpatient facilities, and imaging and pharmacy services.
About FCPT
FCPT, headquartered in Mill Valley, CA, is a real estate investment trust primarily engaged in the ownership, acquisition and leasing of restaurant and retail properties. The Company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries. Additional information about FCPT can be found on the website at www.fcpt.com.
Category: Acquisition
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Ladder Capital (LADR) Reports Earnings Tomorrow: What To Expect
Commercial real estate lender Ladder Capital (NYSE:LADR) will be announcing earnings results this Thursday morning. Here's what investors should know. Ladder Capital missed analysts' revenue expectations by 7.1% last quarter, reporting revenues of $51.28 million, down 18.9% year on year. It was a disappointing quarter for the company, with a significant miss of analysts' tangible book value per share estimates and a significant miss of analysts' EPS estimates. Is Ladder Capital a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Ladder Capital's revenue to decline 21.6% year on year to $56.18 million, a reversal from the 6.5% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.22 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Ladder Capital has missed Wall Street's revenue estimates twice over the last two years. Looking at Ladder Capital's peers in the thrifts & mortgage finance segment, some have already reported their Q2 results, giving us a hint as to what we can expect. PennyMac Mortgage Investment Trust's revenues decreased 1.4% year on year, missing analysts' expectations by 26.1%, and AGNC Investment reported a revenue decline of 367%, falling short of estimates by 141%. AGNC Investment traded up 1.5% following the results. Read our full analysis of PennyMac Mortgage Investment Trust's results here and AGNC Investment's results here. There has been positive sentiment among investors in the thrifts & mortgage finance segment, with share prices up 8.2% on average over the last month. Ladder Capital is up 2.4% during the same time and is heading into earnings with an average analyst price target of $12.79 (compared to the current share price of $11.02). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
28 minutes ago
- Business Wire
A.forall Announces the Direct Commercialization of Sodium Acetate Injection 2mEq/mL
WHITE BEAR LAKE, Minn.--(BUSINESS WIRE)--Through its U.S. subsidiary, Milla Pharmaceuticals Inc., announced the direct commercialization and launch of Sodium Acetate Injection 2mEq/mL in 20mL, 50mL, and 100mL vials. Milla Pharmaceuticals Inc. announced the direct commercialization and launch of Sodium Acetate Injection 2mEq/mL in 20mL, 50mL, and 100mL vials. Share Sodium Acetate Injection, USP is indicated as a source of sodium for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. 'We continue supplying Sodium Acetate in the U.S. throughout this time of shortage as we have been doing over the last four years, but we are now proudly addressing the shortage directly. Thanks to our own commercial organization, we are now able to provide U.S. patients with the medicines they need most in an even more efficient way. 'This important milestone represents the company's continued investment in and increasing internal dedication to serving the U.S. marketplace, especially for products which have been or continue to be reported in shortage,' commented Erik Lazarich, President of U.S. Operations. Please see link for Full Prescribing Information. About & Milla Pharmaceuticals At our mission is all about Making Affordable Medicines Available To All: we develop value-added generic pharmaceuticals, solve product shortages and fill unmet medical needs so that patients can continue their treatment. At the same time, we are reducing costs to the healthcare system and increasing customer convenience for a more sustainable world. Milla Pharmaceuticals Inc., the U.S. subsidiary of is engaged in the development, licensing, acquisition, and commercialization of generic prescription drugs for the U.S. market, focusing on niche injectable and solution products for hospitals and clinics.
Business Wire
28 minutes ago
- Business Wire
Two-Decade Innovation Journey of MagneRide ® Magneto‑Rheological Dampers
MUNICH--(BUSINESS WIRE)--When BWI Group invented and launched the MagneRide ® magneto‑rheological damper in 2002, the company has propelled MagneRide ® on an extraordinary voyage of technical innovation—an adventure of innovation, challenge and bold breakthroughs. Every generation of MagneRide ® embodies BWI Group's relentless pursuit of sharper vehicle dynamics and superior ride comfort. Constant innovation drives the company to perfect its craft, ensuring that each new iteration delivers a palpably better driving experience. MagneRide ® has elevated vehicle handling and comfort while widening its reach from exotic super‑cars and premium nameplates to a far broader market. First Generation: Started from laboratory magic The story begins in a laboratory brimming with curiosity and ambition. In 2002 the first‑generation MagneRide damper was mass produced for the very first time, endowing the debut application—the Cadillac STS—with unprecedented handling prowess. Second Generation: Reinforced system favoured by super‑cars The second‑generation MagneRide ® damper entered the market in 2006. Upgraded magneto‑rheological fluid and a newly designed piston armed the system for both enhanced comfort and assured control in varied conditions. Europe's top super‑car marques soon extended olive branches, validating MagneRide's unparalleled competitiveness in the high‑performance arena. Third Generation: Leap with speed & passion In 2011, the third‑generation MagneRide ® damper's evolution came with dual‑coil technology pushing response frequency to 1,000 adjustments per second. Meanwhile, dual‑layer sealing made the system more durable, and slashed maintenance costs. Fourth Generation: Benchmark in smart‑drive era Arriving in 2020, the latest generation of MagneRide ® suspension system once again stunned the industry and raised the bar for future mobility. Thanks to a cutting‑edge ECU, wheel‑end accelerometers and an IMU, magneto‑rheological fluid reacts in a lightning‑quick 0.5 millisecond. BWI Group's proprietary algorithmic refinements significantly enhance vehicle stability, ushering in a brand‑new driving paradigm. The latest MagneRide ® suspension system endures more than 300,000 km of gruelling service and operates flawlessly in extremes ranging from −30 °C to 105 °C. It conquers every environment beyond the laboratory, and many flagship models have adopted the system. The fourth generation MagneRide ® suspension system paves the way for boundless possibilities in automotive innovation. From the inaugural invention, through the benchmark‑setting fourth generation, every stride attests to BWI Group's tireless quest for technical excellence and precise understanding of market needs.
